Data requirements in a model of the natural history of Alzheimer's disease

Health Care Management Science

Volumn 4, Issue 1, 2001, Pages 13-19

  Chaussalet, Thierry J ^a   Thompson, Wayne A ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

Alzheimer's disease; Incidence; Markov model; Mortality; Natural history

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; HUMAN; INCIDENCE; MASS SCREENING; MORTALITY; PATHOPHYSIOLOGY; PROBABILITY; SENSITIVITY AND SPECIFICITY; THEORETICAL MODEL; VALIDATION STUDY;

AGED; ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MODELS, THEORETICAL; SENSITIVITY AND SPECIFICITY;

EID: 0035261588     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009689329661     Document Type: Article

References (32)

1. N. Bosanquet, Managing the burden of Alzheimer's disease, Geriatric Medicine 29 (1999) 13-14.
2. J. Holmes et al., Managing Alzheimer's disease: the cost of care per patient, British Journal of Health Care Management 4 (1998) 332-337.
3. A. Stewart, Alzheimer's disease: a review of current economic perspectives, Ageing and Society 18 (1998) 585-600.
4. S. Kavanagh et al., Elderly people with cognitive impairment: costing possible changes in the balance of care, Health and Social Care 1 (1993) 69-80.
5. A. Grey and P. Fenn, Alzheimer's disease: the burden of the illness in England, Health Trends 1 (1993) 31-37.
6. J. Scott, Apolipoprotein E and Alzheimer's disease, The Lancet 342 (1993) 696.
7. M.J. Prince, Predicting the onset of Alzheimer's disease using Bayes' theorem, American Journal of Epidemiology 143 (1996) 301-308.
8. P.H. Millard and T.J. Chaussalet, A modelling approach to the development of health and social services for dementia care, Archives of Gerontology and Geriatrics (6) (1998) 325-334.
9. T.J. Chaussalet, P.H. Millard and E. El-Darzi, Evaluating the costs of alternative options for dementia services, Health Care Management Science 1 (1998) 125-131.
10. S.L. Rogers et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Neurology 50 (1998) 136-145.
11. S.L. Rogers and L.T. Friedhoff, Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study, European Neuropsychopharmacology 8 (1998) 67-75.
12. S.L. Rogers et al., Donepezil improves cognition and global function in Alzheimer's disease, Archives of Internal Medicine 158 (1998) 1021-1031.
13. S.L. Rogers et al., The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double-blind, placebo-controlled trial, Dementia 7 (1996) 293-303.
14. A. Stewart, R. Phillips and G. Dempsey, Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil, International Journal of Geriatric Psychiatry 13 (1998) 445-453.
15. B.J. O'Brien et al., Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada, Journal of the American Geriatrics Society 47 (1999) 570-578.
16. L. Jönsson et al., The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model, Clinical Therapeutics 21 (1999) 1230-1240.
17. P.J. Neumann et al., Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease, Neurology 52 (1999) 1138-1145.
18. S. Seshadri et al., Lifetime risk of dementia and Alzheimer's disease, Neurology 49 (1997) 1498-1504.
19. N. Andreason et al., Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden, Neuroepidemiology 18 (1999) 144-155.
20. S. Gao et al., The relationships between age, sex, and the incidence of dementia and Alzheimer's disease, Archives of General Psychiatry 55 (1998) 809-815.
21. C.M. Van Duijn et al., Risk factors for Alzheimer's disease: overview of the EURODEM collaborative re-analysis of case-control studies, International Journal of Epidemiology 20(2) (1991) S4-S11.
22. T.N. Tombaugh and N.J. McIntyre, The mini-mental state examination: a comprehensive review, Joural of the American Geriatric Society 40 (1992) 922-935.
23. L. Bracco, C. Piccini and L. Amaducci, Rate of progression of mental decline in Alzheimer disease: summary of European studies, Alzheimer Disease and Associated Disorders 12 (1998) 347-355.
24. H. Agüero-Torres, L. Fratiglioni and B. Winblad, Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen project, International Journal of Geriatric Psychiatry 13 (1998) 755-766.
25. J.V. Bowler et al., Factors affecting the age of onset and rate of progression of Alzheimer's disease, Journal of Neurology, Neurosurgery and Psychiatry 65 (1998) 184-190.
26. C. Piccini et al., Natural history of Alzheimer's disease: prognostic values of plateaux, Journal of Neurological Sciences 131 (1995) 177-182.
27. M.C. Goldblum et al., Language impairment and rate of cognitive decline in Alzheimer's disease, Dementia 5 (1994) 334-338.
28. G.B. Frisoni et al., Gene dose of the epsilon 4 allele of ApoE and disease progression in sporadic late-onset Alzheimer's disease, Annals of Neurology 37 (1995) 596-604.
29. J. Charlton and M. Murphy, eds., The Health of Adult Britain 1841-1994, Vol. 2, Decennial supplement number 12 (The Stationery Office, London, 1997).
30. J.R. Robinson, The natural history of mental disorder in old age: Alzheimer's disease and depressive illness compared, International Journal of Geriatric Psychiatry 13 (1998) 591-600.
31. A. Briggs and M. Sculpher, An introduction to Markov modelling for economic evaluation, Pharmacoeconomics 13 (1998) 397-409.
32. J.G. Kemeny and J.L. Snell, Finite Markov Chains (Van Nostrand, Princeton/New York, 1960).